Developer docs
API playgroundTry for free, no card

Search company profiles

Truffle Capital

Full company profile

uuid0003q5v

Namestring
Truffle Capital
Legal namestring
Truffle Capital S.A.S.
Websiteurl
truffle.com
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Truffle Capital is an independent European venture capital firm and Business Builder founded in 2001 and headquartered in Paris, France. The firm operates two specialized divisions: BioMedTech (MedTech and Biotech, active since 2001) and Fintech/InsurTech (active since 2015), investing across Europe with selected US exposure. Truffle systematically acts as founder in its BioMedTech portfolio companies, leads financing rounds, and takes board seats as part of a proactive governance model. The firm invests €5-15M per round with follow-on capacity, targeting companies with €5M+ recurring revenue, and historically focuses on radical innovations addressing unmet medical needs sourced from the world's top 50 universities.

Truffle Capital manages €500M in assets under management and has raised €1.2Bn since inception. The active portfolio spans 28 companies, with a cumulative track record of 46 exits and 15 IPOs. Notable portfolio outcomes include Abivax (founded 2013, Nasdaq IPO 2023, $10B market cap in 2025 with +1700% stock performance), Carmat (co-founded 2008 with Airbus Group), Symetis (acquired by Boston Scientific for $435M), and Vexim (acquired by Stryker for $221M in 2017). The firm's revenue model combines management fees on AUM and performance-based carried interest from exits and IPOs.

The most significant recent strategic action is the formation of Carvolix in January 2026, consolidating three MedTech companies (Affluent Medical, Caranx Medical, and Artedrone) into a cardiovascular platform targeting AI-driven mini-robotics and biomimetic implants for heart valve replacement and brain stroke treatment in a $25B+ market by 2030. Co-investment with Edwards Lifesciences and FDA clearance of TAVIPILOT Soft in July 2025 validate the platform's commercial trajectory. The firm is led by co-founders and co-CEOs Philippe Pouletty, M.D. (inventor of 39 patents, Stanford Hall of Fame) and Bernard-Louis Roques (founded first European FinTech Incubator), with Henri Moulard as Chairman.

Short descriptiontext

Truffle Capital is an independent European venture capital firm and Business Builder founded in 2001, headquartered in Paris, that creates and finances deep-tech companies in BioMedTech and Fintech/InsurTech, managing €500M AUM across 28 active portfolio companies with 46 historical exits and 15 IPOs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital firm, biomedtech investments, fintech venture capital, business builder model, private equity investments
NAICS code2 codes
  • Finance and Insurance52
  • Funds, Trusts, and Other Financial Vehicles525
Product category
Venture Capital
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Management Fees
TypeSubscription Recurring
Description

Standard VC management fees on assets under management

truffle.com
2Carried Interest
TypeLicensing Royalties
Description

Performance-based carried interest from successful fund exits and IPOs

truffle.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Truffle Capital is an independent European venture capital and business builder firm that creates, finances, and develops technology companies in BioMedTech (MedTech & Biotech) and Fintech/InsurTech. The firm systematically acts as founder in BioMedTech companies, leads financing rounds with investment tickets of €5-15M, and provides proactive governance with board seats. Since 2001, it has raised over €1.2 billion, manages €500M in assets across 28 active portfolio companies, and has delivered 46 exits including 15 IPOs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • €1.2Bn raised since inception across all funds
+3 more records
Product overview1 text field

Truffle Capital is a venture capital firm and Business Builder that has been creating, financing, and supporting technology companies in BioMedTech and Fintech since 2001. Their BioMedTech portfolio includes medical device and biotech companies, while their Fintech portfolio spans payments, insurance technology, digital assets, and data solutions. Key products include TAVIPILOT Soft (AI-guided TAVI surgery software), TAVIPILOT Robot (mini-robotic system for heart valve procedures), Carvolix (cardiovascular AI-robotics platform), Hydrosat (AI satellite analytics), and various biotech products including Abivax. Truffle Capital also publishes research indices including the Truffle Medtech 10 Index and Truffle 100 ranking of European fintech companies.

Product and service5 records
1BioMedTech Venture Fund
CategoryVenture Capital Fund
Description

European venture capital fund investing in MedTech and Biotech companies. Truffle acts as systematic founder, leads financing rounds with €5-15M tickets plus follow-on, and provides proactive governance with board seats. €278M AUM, 32 companies backed since 2001, €3.1Bn equity raised by portfolio companies.

2Fintech Venture Fund
CategoryVenture Capital Fund
Description

European venture capital fund investing in Fintech and InsurTech companies across payments, SME finance, credit, digital assets, regtech, cybersecurity, and process automation. 23 investments since 2015, 7 exits, 16 active portfolio companies, team of 7 nationalities.

3Business Builder Services
CategoryBusiness Building / Company Creation Services
Description

Proprietary company creation and development services in BioMedTech: Truffle Capital creates companies from patent applications or strengthens existing companies in the European ecosystem, focusing on radical innovations addressing unmet medical needs. Includes company founding, leadership, board seats, and operational support.

4Truffle 100
CategoryResearch Publication
Description

Leading annual research publication on EU software vendors, co-published by Sopra Steria, Finance Innovation, BPCE, and Truffle Capital. Has become a key barometer of France's most dynamic fintechs; the 2025 edition highlights sector's €2.5bn cumulative revenue and 13,000 jobs.

5Truffle Medtech 10 Index
CategoryResearch Index
Description

First ranking of top 10 worldwide market capitalizations in interventional MedTech for pre-commercial and early commercial listed companies. Carvolix entered at #1 in Europe and #6 worldwide.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Sopra Steria
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-01-01
Description

Co-organizer of Fintech 100 annual ranking with Sopra Steria, Finance Innovation, and BPCE. The 2025 edition covers €2.5bn cumulative revenue and 13,000 jobs.

truffle.com
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-01-01
Description

Co-organizer of Fintech 100 annual ranking with Sopra Steria, Finance Innovation, BPCE, and Truffle Capital.

Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-01-01
Description

Co-organizer of Fintech 100 annual ranking with Sopra Steria, Finance Innovation, BPCE, and Truffle Capital.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

Co-founded SpikImm with Institut Pasteur in 2021, a biotech company developing monoclonal antibodies for viral infections in transplant patients.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sofinnova is a Paris-based European venture capital firm with a long-standing focus on life sciences (Biotech and MedTech), making it a direct peer to Truffle Capital's BioMedTech franchise. Both firms combine deep scientific networks with lead-investor and board governance models across European healthcare innovation.

TypeDirect peer
Description

Seventure Partners is a Paris-based VC/PE firm investing across life sciences, digital, and Fintech, with active fund management and a similar pan-European deal footprint to Truffle Capital. Both firms operate lead-investor models with active board participation and Fintech/digital ecosystems.

TypeDirect peer
Description

Andera Partners (formerly Edmond de Rothschild Investment Partners) is a Paris-based private equity firm with dedicated life sciences and growth capital strategies, comparable to Truffle Capital's BioMedTech and growth-stage thesis. Both firms are AMF-regulated French managers pursuing European lead-investor opportunities.

TypeBroad incumbent
Description

Bpifrance is the French public investment bank and a co-organizer with Truffle of the Fintech 100; it deploys public capital across VC, growth, and SME finance in France. While not a pure VC peer, Bpifrance frequently co-invests with Truffle in BioMedTech and Fintech rounds, making it both a competitor and a strategic partner.

TypeDirect peer
Description

Novo Holdings (via Novo Ventures) is a Danish-backed life sciences venture investor with deep European biotech expertise and global deal flow, directly comparable to Truffle Capital's BioMedTech franchise. Both firms pursue lead-investor roles in clinical-stage biotech and MedTech across Europe.

6EQT Life Sciences
TypeBroad incumbent
Description

EQT Life Sciences (formerly LSP) is the life sciences arm of EQT, a major European private equity platform; it invests across European Biotech and MedTech with larger fund sizes than Truffle Capital. Comparable in thesis (European lead investor in life sciences) but broader in scale and geographic mandate.

TypeDirect peer
Description

Karista is a Paris-based early-stage VC with Healthcare and Tech/Fintech verticals, comparable to Truffle Capital's European focus and stage preferences. Both firms are AMF-regulated and serve as lead/active investors in French and broader European startups.

TypeBroad incumbent
Description

Eurazeo is a major French-listed private investment firm with growth and venture strategies including healthcare and deep tech. As a broader and more diversified incumbent than Truffle, it competes for similar European growth-stage BioMedTech and Fintech deals but at a larger fund scale.

TypeDirect peer
Description

Indaco Venture Partners is an Italian VC firm managing multiple early-stage and life sciences funds in Europe, comparable in stage and sector to Truffle Capital. Both pursue lead investments in European deep tech and life sciences with active governance.

TypeDirect peer
Description

Forbion is a leading European life sciences VC firm focused on biotech and MedTech, directly comparable to Truffle Capital's BioMedTech franchise. Both firms operate lead-investor models in European clinical-stage healthcare with active board involvement.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment61 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Truffle Capital

Venture Capitaltruffle.com

Truffle Capital is an independent European venture capital firm and Business Builder founded in 2001, headquartered in Paris, that creates and finances deep-tech companies in BioMedTech and Fintech/InsurTech, managing €500M AUM across 28 active portfolio companies with 46 historical exits and 15 IPOs.

What Truffle Capital does

Truffle Capital is an independent European venture capital firm and Business Builder founded in 2001 and headquartered in Paris, France. The firm operates two specialized divisions: BioMedTech (MedTech and Biotech, active since 2001) and Fintech/InsurTech (active since 2015), investing across Europe with selected US exposure. Truffle systematically acts as founder in its BioMedTech portfolio companies, leads financing rounds, and takes board seats as part of a proactive governance model. The firm invests €5-15M per round with follow-on capacity, targeting companies with €5M+ recurring revenue, and historically focuses on radical innovations addressing unmet medical needs sourced from the world's top 50 universities.

Truffle Capital manages €500M in assets under management and has raised €1.2Bn since inception. The active portfolio spans 28 companies, with a cumulative track record of 46 exits and 15 IPOs. Notable portfolio outcomes include Abivax (founded 2013, Nasdaq IPO 2023, $10B market cap in 2025 with +1700% stock performance), Carmat (co-founded 2008 with Airbus Group), Symetis (acquired by Boston Scientific for $435M), and Vexim (acquired by Stryker for $221M in 2017). The firm's revenue model combines management fees on AUM and performance-based carried interest from exits and IPOs.

The most significant recent strategic action is the formation of Carvolix in January 2026, consolidating three MedTech companies (Affluent Medical, Caranx Medical, and Artedrone) into a cardiovascular platform targeting AI-driven mini-robotics and biomimetic implants for heart valve replacement and brain stroke treatment in a $25B+ market by 2030. Co-investment with Edwards Lifesciences and FDA clearance of TAVIPILOT Soft in July 2025 validate the platform's commercial trajectory. The firm is led by co-founders and co-CEOs Philippe Pouletty, M.D. (inventor of 39 patents, Stanford Hall of Fame) and Bernard-Louis Roques (founded first European FinTech Incubator), with Henri Moulard as Chairman.

Truffle Capital firmographics

Firmographics
Name
Truffle Capital
Legal name
Truffle Capital S.A.S.
Website
https://truffle.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
51–100 employees
Short description
Truffle Capital is an independent European venture capital firm and Business Builder founded in 2001, headquartered in Paris, that creates and finances deep-tech companies in BioMedTech and Fintech/InsurTech, managing €500M AUM across 28 active portfolio companies with 46 historical exits and 15 IPOs.
Ownership category
akta.pro rank

Where Truffle Capital is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Truffle Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Management Fees: Standard VC management fees on assets under management
  2. Carried Interest: Performance-based carried interest from successful fund exits and IPOs

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Truffle Capital product offering

Product offering

Core offering

Truffle Capital is an independent European venture capital and business builder firm that creates, finances, and develops technology companies in BioMedTech (MedTech & Biotech) and Fintech/InsurTech. The firm systematically acts as founder in BioMedTech companies, leads financing rounds with investment tickets of €5-15M, and provides proactive governance with board seats. Since 2001, it has raised over €1.2 billion, manages €500M in assets across 28 active portfolio companies, and has delivered 46 exits including 15 IPOs.

Product overview

Truffle Capital is a venture capital firm and Business Builder that has been creating, financing, and supporting technology companies in BioMedTech and Fintech since 2001. Their BioMedTech portfolio includes medical device and biotech companies, while their Fintech portfolio spans payments, insurance technology, digital assets, and data solutions. Key products include TAVIPILOT Soft (AI-guided TAVI surgery software), TAVIPILOT Robot (mini-robotic system for heart valve procedures), Carvolix (cardiovascular AI-robotics platform), Hydrosat (AI satellite analytics), and various biotech products including Abivax. Truffle Capital also publishes research indices including the Truffle Medtech 10 Index and Truffle 100 ranking of European fintech companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • BioMedTech Venture Fund European venture capital fund investing in MedTech and Biotech companies. Truffle acts as systematic founder, leads financing rounds with €5-15M tickets plus follow-on, and provides proactive governance with board seats. €278M AUM, 32 companies backed since 2001, €3.1Bn equity raised by portfolio companies.
  • Fintech Venture Fund European venture capital fund investing in Fintech and InsurTech companies across payments, SME finance, credit, digital assets, regtech, cybersecurity, and process automation. 23 investments since 2015, 7 exits, 16 active portfolio companies, team of 7 nationalities.
  • Business Builder Services Proprietary company creation and development services in BioMedTech: Truffle Capital creates companies from patent applications or strengthens existing companies in the European ecosystem, focusing on radical innovations addressing unmet medical needs. Includes company founding, leadership, board seats, and operational support.
  • Truffle 100 Leading annual research publication on EU software vendors, co-published by Sopra Steria, Finance Innovation, BPCE, and Truffle Capital. Has become a key barometer of France's most dynamic fintechs; the 2025 edition highlights sector's €2.5bn cumulative revenue and 13,000 jobs.
  • Truffle Medtech 10 Index First ranking of top 10 worldwide market capitalizations in interventional MedTech for pre-commercial and early commercial listed companies. Carvolix entered at #1 in Europe and #6 worldwide.

Quantifiable outcome

  • €1.2Bn raised since inception across all funds
  • +3 more outcomes

Companies that use Truffle Capital

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Truffle Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature1 record

Truffle Capital partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Sopra SteriacoreGTM or Marketing Partner · 1 January 2025Co-organizer of Fintech 100 annual ranking with Sopra Steria, Finance Innovation, and BPCE. The 2025 edition covers €2.5bn cumulative revenue and 13,000 jobs.
  • Finance InnovationcoreGTM or Marketing Partner · 1 January 2025Co-organizer of Fintech 100 annual ranking with Sopra Steria, Finance Innovation, BPCE, and Truffle Capital.
  • BPCEcoreGTM or Marketing Partner · 1 January 2025Co-organizer of Fintech 100 annual ranking with Sopra Steria, Finance Innovation, BPCE, and Truffle Capital.
  • Institut PasteurcoreStrategic or Co-development Partner · 1 January 2021Co-founded SpikImm with Institut Pasteur in 2021, a biotech company developing monoclonal antibodies for viral infections in transplant patients.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Truffle Capital competitors and assessment

Company assessment

Direct peers

  • Sofinnova Partners: Sofinnova is a Paris-based European venture capital firm with a long-standing focus on life sciences (Biotech and MedTech), making it a direct peer to Truffle Capital's BioMedTech franchise. Both firms combine deep scientific networks with lead-investor and board governance models across European healthcare innovation.
  • Seventure Partners: Seventure Partners is a Paris-based VC/PE firm investing across life sciences, digital, and Fintech, with active fund management and a similar pan-European deal footprint to Truffle Capital. Both firms operate lead-investor models with active board participation and Fintech/digital ecosystems.
  • Andera Partners: Andera Partners (formerly Edmond de Rothschild Investment Partners) is a Paris-based private equity firm with dedicated life sciences and growth capital strategies, comparable to Truffle Capital's BioMedTech and growth-stage thesis. Both firms are AMF-regulated French managers pursuing European lead-investor opportunities.
  • Novo Holdings (Novo Ventures): Novo Holdings (via Novo Ventures) is a Danish-backed life sciences venture investor with deep European biotech expertise and global deal flow, directly comparable to Truffle Capital's BioMedTech franchise. Both firms pursue lead-investor roles in clinical-stage biotech and MedTech across Europe.
  • Karista (formerly Ventech): Karista is a Paris-based early-stage VC with Healthcare and Tech/Fintech verticals, comparable to Truffle Capital's European focus and stage preferences. Both firms are AMF-regulated and serve as lead/active investors in French and broader European startups.
  • Indaco Venture Partners: Indaco Venture Partners is an Italian VC firm managing multiple early-stage and life sciences funds in Europe, comparable in stage and sector to Truffle Capital. Both pursue lead investments in European deep tech and life sciences with active governance.
  • Forbion: Forbion is a leading European life sciences VC firm focused on biotech and MedTech, directly comparable to Truffle Capital's BioMedTech franchise. Both firms operate lead-investor models in European clinical-stage healthcare with active board involvement.

Broad incumbents

  • Bpifrance: Bpifrance is the French public investment bank and a co-organizer with Truffle of the Fintech 100; it deploys public capital across VC, growth, and SME finance in France. While not a pure VC peer, Bpifrance frequently co-invests with Truffle in BioMedTech and Fintech rounds, making it both a competitor and a strategic partner.
  • EQT Life Sciences: EQT Life Sciences (formerly LSP) is the life sciences arm of EQT, a major European private equity platform; it invests across European Biotech and MedTech with larger fund sizes than Truffle Capital. Comparable in thesis (European lead investor in life sciences) but broader in scale and geographic mandate.
  • Eurazeo: Eurazeo is a major French-listed private investment firm with growth and venture strategies including healthcare and deep tech. As a broader and more diversified incumbent than Truffle, it competes for similar European growth-stage BioMedTech and Fintech deals but at a larger fund scale.

Market position

Strengths5 records

Weaknesses5 records

Customer concentration

Truffle Capital social profiles

Digital presence

Truffle Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Truffle Capital leadership team

Management profile

Number of profiles

Profiles5 records

Truffle Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Truffle Capital M&A and investment

M&A and investment

M&A

Investments61 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Truffle Capital

What does Truffle Capital do?

Truffle Capital is an independent European venture capital and business builder firm that creates, finances, and develops technology companies in BioMedTech (MedTech & Biotech) and Fintech/InsurTech. The firm systematically acts as founder in BioMedTech companies, leads financing rounds with investment tickets of €5-15M, and provides proactive governance with board seats. Since 2001, it has raised over €1.2 billion, manages €500M in assets across 28 active portfolio companies, and has delivered 46 exits including 15 IPOs.

Is Truffle Capital a public or private company?

Truffle Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Truffle Capital founded?

Truffle Capital was founded in 2001. It employs 51 to 100 people.

Where is Truffle Capital based?

Truffle Capital is headquartered in Paris, France, in the Europe region.

How does Truffle Capital make money?

Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest.

Who are Truffle Capital's main competitors?

Direct peers on record are Sofinnova Partners, Seventure Partners, Andera Partners, Novo Holdings (Novo Ventures), Karista (formerly Ventech), Indaco Venture Partners and Forbion. Broad incumbents are Bpifrance, EQT Life Sciences and Eurazeo.

Does Truffle Capital have an API?

No public API is recorded for Truffle Capital.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinanzNachrichten.deTruffle Carvolix Elysée - Franco-Saudi Medical Cooperation. -2-Carvolix SA, Truffle Capital and Carvolix Saudi LLC announced on 24 August 2026 the launch of the SAF-MD Saudi-French Medical Exchange and Cooperation Program, signed during Crown Prince Mohammed bin Salman's visit to France. The three-year, renewable programme covers interventional cardiology, cardiac and vascular surgery, heart valve replacement and neurovascular emergencies, with exchanges of six months to two years. Carvolix Saudi LLC, wholly owned by Carvolix SA, is intended to build a MedTech manufacturing facility.FinanzNachrichten.deTruffle - Carvolix - Elysée - MBS - English. -2-Carvolix SA, a French MedTech company founded by Truffle Capital, announced on 24 August 2026 the incorporation of its wholly owned Saudi subsidiary, Carvolix Saudi LLC, in Riyadh, with a potential manufacturing facility serving Saudi, European, Asian and possibly North American markets. The facility could create about 250 jobs, with commercial production of TAVIPILOT scheduled for 2028. Financing remains to be defined.FinanzNachrichten.deTruffle Carvolix Elysée - Franco-Saudi Medical Cooperation.Carvolix SA, Truffle Capital and Carvolix Saudi LLC announced on 24 August 2026 the launch of the SAF-MD Saudi-French Medical Exchange and Cooperation Program, signed during Crown Prince Mohammed bin Salman's visit to France. The three-year, renewable program covers interventional cardiology, cardiac and vascular surgery, heart valve replacement and neurovascular emergencies, with exchanges of six months to two years. Carvolix Saudi LLC may build a MedTech manufacturing facility serving Saudi, European, Asian and North American markets.FinanzNachrichten.deTruffle - Carvolix - Elysée - MBS - English.Carvolix SA, a French interventional MedTech company founded by Truffle Capital, announced on 24 August 2026 the potential establishment of its wholly owned Saudi subsidiary, Carvolix Saudi LLC, to build a manufacturing facility serving Saudi, European, Asian and potentially North American markets. The facility could create about 250 jobs, with commercial production of TAVIPILOT scheduled for 2028. Financing via equity, debt and grants is still being developed.FRENCHWEB.FRQONTO veut racheter ACASI à la barre : la nouvelle vague de distressed M&A arrive dans la French TechQonto filed a takeover offer to buy ACASI's assets for €750,000, including staff, tech, and contracts. The deal follows ACASI's judicial restructuring and a failed prior acquisition due to financial concerns.Venture Capital Access OnlineHydrosat Raises $60M in Series B Funding to Accelerate GrowthHydrosat, a provider of thermal infrared satellite data and AI-powered analytics, announced the close of $60 million in Series B funding co-led by Hartree Partners, Subutai Capital Partners, and Space 4 Earth, with participation from Truffle Capital, Luxembourg Future Fund, OTB Ventures, and other investors. The funding will support global expansion into regions including Central Asia, MENA, India, and Latin America, as well as the next phase of constellation development and product evolution for the company's thermal satellite fleet. The company currently operates two thermal infrared satellites capable of collecting over 10 million square kilometers of imagery daily, serving customers including NOAA, NRO, Bayer, SupPlant, and Nutradrip.IBS IntelligenceLevenue acquires Cake and secures €8m in Series A from Truffle CapitalLevenue secured €8 million in Series A funding led by Truffle Capital and acquired Cake to enhance its revenue-based financing platform. The acquisition of Cake's open banking technology aims to improve risk profiling accuracy, supporting Levenue's expansion into the European Union, including a planned launch in France in Q1 2024. This strategic move builds on Levenue's track record of facilitating over €300 million in financing for subscription-based businesses.Institutional Asset ManagerTruffle continues democratisation of private markets themeTruffle Private Markets, a European private markets solutions provider, broadens access to private equity, venture capital, and other assets for wealth managers and family offices. It closed 21 private equity fund commitments in 2022, doubling its prior-year achievements, and manages five annual programmes. The firm aims to become a significant player in the democratisation space.Next FinanceObat lève 6 M€ auprès de Truffle Capital, Evolem et Holnest pour digitaliser la gestion des TPE et PME du BTPObat, a SaaS platform for construction management, has raised €6 million in seed funding led by Truffle Capital, with participation from Evolem and Club Holnest. The company intends to use the capital to accelerate its growth in the French market, aiming to reach 10,000 active clients and €3 million in annual recurring revenue by the end of 2022.FRENCHWEB.FR[Seed] BTP : Obat lève 6 millions d’euros auprès de Truffle Capital pour digitaliser la gestion des TPE et PMEFrench startup Obat has raised 6 million euros from investors Truffle Capital, Evolem, and Holnest to fund the digitalization of management tools for small and medium-sized construction enterprises. The company plans to use these funds to accelerate its growth, aiming to reach 10,000 active clients and 3 million in annual recurring revenue by the end of 2022.